Abstract:Catarina Falcão de Campos, 1, 2 Isabel Conceição 1, 2 1 Department of Neurosciences and Mental Health, Centro Hospitalar Universitário de Lisboa-Norte, Lisbon, Portugal; 2 Instituto de Fisiologia, Instituto de Medicina Molecular, Centro de Estudos Egas Moniz, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal Correspondence: Catarina Falcão de Campos, Department of Neurosciences, Hospital de Santa Maria, Av. Professor Egas Moniz, Lisbon, 1648-028, Portugal, Tel/Fax + 351 21 780521, Email Hereditary amyloid transthyretin (ATTRv) amyloidosis is a devastating hereditary multisystemic disease affecting predominantly the peripheral and autonomic nervous systems and the heart. ATTRv is caused by mutations in the transthyretin ( TTR ) gene, leading to extracellular deposition of amyloid fibrils in multiple organs including the peripheral nervous system. If untreated, it is associated with a fatal outcome 10– 12 years after disease onset. Different treatments are available for patients with ATTRv polyneuropathy. Tafamidis 20 mg is approved in Europe since 2011 for early stages of ATTRv polyneuropathy (stage I – able to walk without support) and it is recommended as first-line therapy in these patients. Tafamidis is a TTR stabilizer that selectively binds to TTR and kinetically stabilizes both wild-type native TTR and mutant TTR. Consequently, it has the potential to prevent the amyloidogenic cascade initiated by TTR tetramer dissociation into its monomers and subsequent misfolding and aggregation. Tafamidis is an oral drug, taken once per day, with proved efficacy, safety and tolerability in ATTRv-PN patients as demonstrated in different clinical trials and open-label extension studies as well in clinical practice setting with around 10 years of experience. Tafamidis treatment started in the earliest stages of the disease is associated with better neurological outcomes. A multidisciplinary approach in referral centres is also fundamental for monitoring patients to assess individual response to treatment. Keywords: hereditary amyloid transthyretin amyloidosis, transthyretin, tafamidis, familial amyloid polyneuropathy, amyloidosis, TTR stabilizer Hereditary amyloid transthyretin (ATTRv) amyloidosis with polyneuropathy (ATTRv-PN), also commonly known as familial amyloid polyneuropathy (FAP), is a devastating hereditary multisystemic disease leading to progressive disability with a fatal outcome after 10–12 years of disease onset, if left untreated. 1 The disease is characterized by deposition of amyloid fibrils in different organs and tissues, being the peripheral and autonomic nervous systems and the heart the main afflicted organs. 2 It results from mutations in the transthyretin ( TTR ) gene, with an autosomal dominant inheritance, which will be responsible for the destabilization of the tetrameric structure of TTR protein with consequent dissociation into its monomers and further misfolding and formation of the amyloid fibril aggregates. 3 In the last decades, different disease-modifying treatments have been proven to be effective and safe in attenuating disease progression. 4 Liver transplantation (LT) was the first approved treatment by eliminating the production of the amyloidogenic mutated TTR produced by the liver. 5 However, although its efficacy, there are some limitations: it is a major surgical procedure inevitably associated with its inherent risks; there is a limited number of compatible grafts; some patients still have disease progression due to continued amyloid fibril formation of wild-type TTR; amyloid fibril production in the eye and choroid plexus endures contributing to severe eye and central nervous system involvement in the later stages of the disease. 6 For these reasons, there was an active need for development of new treatments. Considering the pathogenic TTR pathway, stabilizing the mutant TTR protein, and then preventing its dissociation and consequent amyloid fibril formation, would be an optimal target for newer agents. 7 Oral TTR stabilizers (such as Tafamidis) were then developed and approved for the early stages of the disease. 7 Tafamidis 20 mg, available as a soft capsule taken once per day, was initially approved for commercial use in Europe in 2011 and then approved in other countries such as Japan, Mexico and Argentina, being currently available in more than 40 countries in where it is used as a first-line treatment in the early stage (stage I – able to walk without support) of the disease. 8 More recently, genetic modifiers agents were also approved for ATTRv-PN with encouraging results and safety. 9,10 In this review, we will assess the discovery and development of Ta -Abstract Truncated-

Real-life experience with inotersen at CEPARM, Hospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de Janeiro

Switching from inotersen to eplontersen in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: analysis from NEURO-TTRansform

Characteristics of Patients with Hereditary Transthyretin Amyloidosis-Polyneuropathy (ATTRv-PN) in NEURO-TTRansform, an Open-label Phase 3 Study of Eplontersen

Real‐life experience with disease‐modifying drugs in hereditary transthyretin amyloid polyneuropathy: A clinical and electrophysiological appraisal

Patisiran treatment in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy after liver transplantation

Long-term treatment of hereditary transthyretin amyloidosis with patisiran: multicentre, real-world experience in Italy

Characterization and natural history of different phenotypes in hereditary transthyretin amyloidosis: 40-year experience at a single Italian referral centre

Effect of Eplontersen on Cardiac Structure and Function in Patients With Hereditary Transthyretin Amyloidosis

Patisiran for the treatment of patients with p.Ile88Leu hereditary transthyretin amyloidosis: an Italian real-life experience

Transthyretin amyloid polyneuropathy in France: A cross-sectional study with 413 patients and real-world tafamidis meglumine use (2009–2019)

Primary Results From APOLLO-B Open-label Extension Study Of Patisiran In Patients With Transthyretin Cardiac Amyloidosis

Updated Evaluation of the Safety, Efficacy and Tolerability of Tafamidis in the Treatment of Hereditary Transthyretin Amyloid Polyneuropathy

2020 Peripheral Nerve Society Virtual Event

Impact of Baseline Neuropathy Severity on Vutrisiran Treatment Response in the Phase 3 HELIOS-A Study

Clinical and genetic profiles of patients with hereditary and wild-type transthyretin amyloidosis: the Transthyretin Cardiac Amyloidosis Registry in the state of São Paulo, Brazil (REACT-SP)

Estimating Meaningful Differences in Measures of Neuropathic Impairment, Health‐Related Quality of Life, and Nutritional Status in Patients With Hereditary Transthyretin Amyloidosis

A mini-review of Vutrisiran and Eplontersen in hereditary transthyretin-mediated amyloidosis with polyneuropathy

137 PRIMARY RESULTS FROM APOLLO-B, A PHASE 3 STUDY OF PATISIRAN IN PATIENTS WITH TRANSTHYRETIN-MEDIATED AMYLOIDOSIS WITH CARDIOMYOPATHY

Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy

Tafamidis: A Review in Transthyretin Amyloidosis with Polyneuropathy

Efficacy and safety of patisiran for ATTRv-PN: a systematic review and meta-analysis